PALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the
Second Prix Galien Award for Daiichi Sankyo and AstraZeneca’s Enhertu following receipt of the Prix Galien USA Award in 2024
Enhertu® (trastuzumab deruxtecan) has been awarded the 2026 International Prix Galien
Continued strong commercial performance and 12 positive Phase III programme readouts in the year to date
AstraZeneca:
Revenue and EPS summary
9M 2026
% Change
Q3 2026
%
DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay
Campaign encourages people to take a "time out" to learn more about cancer biomarker testing, which can guide more personalized cancer treatment decisions
AstraZeneca today announced the launch of Meet Your
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1
First EU approval of
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), AstraZeneca (NYSE:AZN), and Roche (OTCQX:RHHBY) are among the biopharma companies committing billions of
PALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York.
Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint
Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this
TAGRISSO plus savolitinib extended median overall survival by nearly five months
SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing
Novel combination demonstrated a median overall survival of nearly two years, the longest benefit ever reported in extensive stage disease in a Phase III trial
Results reinforce IMFINZI as the backbone immunotherapy
More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery
Data demonstrated statistically significant and clinically
Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapy
Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placebo
TEZSPIRE
CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients
SAFFRON results will highlight clinical benefit of adding
